Evidence review · from the 250-topic plan
Stopping semaglutide: what the STEP-1 extension actually measured
The cleanest data on life after semaglutide comes from following STEP-1 participants for a year off treatment: on average they regained about two-thirds of the weight they had lost, and the cardiometabolic improvements — blood pressure, lipids, HbA1c — largely retreated with the pounds. The message isn't "never stop"; it's that stopping is a medical transition deserving a plan: muscle banked in advance, a maintenance framework, a pre-agreed tripwire for re-evaluation, and clear answers about what re-entry will cost. This page turns the extension data into that plan, semaglutide-specifically.
What the extension actually found
STEP 1 established the headline — roughly 14.9% average weight loss at 68 weeks on 2.4 mg weekly. The extension asked the harder question by following participants for 52 more weeks after both drug and lifestyle support ended. The averages: about two-thirds of lost weight regained within the year, with net loss from the original baseline shrinking to the mid-single digits, and the accompanying improvements in blood pressure, lipids and glycemia reverting substantially toward where they started. Distribution honesty applies here too — some people kept most of their loss, some regained past baseline — and the withdrawal of support along with drug means the study measures stopping-everything, which is exactly how most real-world stops happen.
The same story tirzepatide tells, with one nuance
Tirzepatide's withdrawal experiment (SURMOUNT-4) found regain of roughly half of lost weight in a year off — directionally identical, arithmetically a bit gentler, though design differences (blinded placebo swap versus open follow-up, different lead-in lengths) make precise cross-trial comparison unwise. The convergent conclusion is the useful one: for both molecules, the effect is maintained by the treatment, and the biology driving regain — rising ghrelin, falling satiety signaling, suppressed energy expenditure — doesn't care which agonist you stopped. Chronic-condition framing beats willpower framing on the evidence, every time.
A sema-specific off-ramp
Name the reason, out loud, with a clinician — side effects, pregnancy planning, cost, goal reached — because the reason picks the plan, and some timelines (pregnancy in particular) are medical rules rather than preferences. Bank the muscle first: resistance training plus protein on the order of 1.2–1.6 g/kg/day, started months before the last injection, is the best-supported way to shape what stays. Consider the step-down question: semaglutide's ladder (2.4 → 1.7 → 1.0 and below) gives natural test rungs for where appetite control holds; there's no formal taper trial, but structured step-downs are a common clinical approach worth planning rather than improvising. Set the tripwire in writing: a regain percentage, a waist number, or a hunger pattern that triggers re-evaluation — decided now, while you're not hungry. Price the return before you leave: sema's audited floor in our field is $119 standard and $110 microdose (evidence caveat attached) on locked twelve-month rates; whether a locked rate survives a lapse is the question to get answered in writing, because the cheapest restart is the one negotiated before you needed it. And if a restart conversation turns into a molecule conversation, the head-to-head evidence lives at the SURMOUNT-5 review.
FAQ
How much weight comes back after stopping semaglutide?
On trial averages, about two-thirds of lost weight within one year off treatment (STEP-1 extension), with cardiometabolic improvements largely reverting — and wide individual variation around that mean.
Do blood pressure and cholesterol benefits last after stopping?
Mostly no — the extension found those improvements retreating substantially alongside the regain, which is a core argument for planning maintenance rather than assuming permanence.
Is there an official semaglutide taper?
No formal protocol exists; stepping down the dose ladder to find where appetite control holds is a common clinician-guided approach.
What does restarting cost?
Program-dependent: promo doors re-price returners, terms may restart, and locked rates may or may not survive a lapse. The audited sema floor here is $119/$110 on twelve-month plans — confirm re-entry terms in writing before stopping.
Sources
- Wilding JPH, et al. STEP 1, NEJM 2021; and the STEP-1 off-treatment extension publication.
- SURMOUNT-4 randomized withdrawal (tirzepatide) for cross-molecule context.
- Metabolic-adaptation and appetite-hormone literature post weight loss.
- Audited semaglutide plan pricing — the open dataset, 2026-08-14.